Journal · Updated 2026-08-11

The GLP-1 Glossary: Every Term That Gates Your Price, Coverage, or Safety, Defined Straight

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

503A pharmacy

A traditional compounding pharmacy that prepares medications for specific patients, one prescription at a time, under state board oversight with federal rules layered on. The lane most legitimately individualized compounded GLP-1 prescriptions travel — and the lane that cannot lawfully mass-produce for subscriber volume.

503B outsourcing facility

An FDA-registered facility permitted to compound larger batches without patient-specific prescriptions, under federal cGMP-style requirements. The pathway most large subscription compounded-GLP-1 programs rely on — and the one the FDA's April 2026 proposal would close for semaglutide, tirzepatide, and liraglutide if finalized.

503B bulks list

The FDA's list of bulk drug substances that outsourcing facilities may compound from. A molecule's presence on the list is what makes factory-scale compounding of it lawful; removal — as proposed for the GLP-1s — ends that lane.

A1c (HbA1c)

A blood measure of average glucose over roughly three months, expressed as a percentage. The diabetes-door documentation anchor: prior authorizations for T2D-indicated GLP-1s typically want the value, the date, and the treatment history around it.

Adverse event report

A report to a regulator (in the US, FDA's MedWatch) describing a suspected harm associated with a product. Signal, not verdict — reports establish patterns worth investigating, and the compounded-GLP-1 tallies (455-plus for semaglutide, 320-plus for tirzepatide by early 2025) trace heavily to at-home dosing errors.

All-in price

This site's ranking basis: the monthly figure with membership, provider access, and shipping folded in. Exists because a low sticker with a fee underneath is not a low price.

BALANCE model

The CMS program (announced December 2025) letting state Medicaid agencies and Part D plans cover GLP-1s at federally negotiated prices with standardized criteria and a manufacturer-funded lifestyle program. Medicaid applications closed July 31, 2026; live coverage by January 1, 2027.

Bariatric surgery

Weight-loss surgery (gastric bypass, sleeve gastrectomy, and related procedures). Appears in coverage policy as the expensive alternative some criteria are written to avert — Michigan's 2026 Medicaid test literally requires GLP-1 use as a measure to avoid it.

Beyond-use date (BUD)

The compounded-product analog of an expiration date: the point after which a preparation should not be used, set by stability considerations. Shorter than commercial expiry as a rule — check the vial, not your assumption.

BMI (body mass index)

Weight in kilograms divided by height in meters squared. A blunt but universal gatekeeping number: FDA weight-management labels start at 30 (or 27 with a comorbidity), and 2026's strict Medicaid states moved their lines to 35, 37, or 40.

Boxed warning

The FDA's most prominent label warning. Every semaglutide and tirzepatide product carries one for thyroid C-cell tumors observed in rodents — the reason a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication.

Cash-pay

Paying without insurance involvement. The entire compounded market and the manufacturer-direct programs run on it; its virtue is speed and certainty, its cost is bearing the full price.

Certificate of analysis (COA)

Third-party lab documentation of a specific lot's identity, potency, and sterility testing. The single document that separates a verifiable compounded product from a trust-me one; a legitimate pharmacy can produce it on request.

cGMP

Current Good Manufacturing Practice — the federal quality-system regulations for drug manufacturing. 503B facilities operate under cGMP-style requirements; 503A pharmacies operate under pharmacy-practice standards instead, one of the structural differences between the lanes.

Compounded drug

A medication prepared by a licensed pharmacy rather than the original manufacturer, lawful under specific conditions and never FDA-approved. Legal is not the same as approved — the distinction the FDA's 2026 letters exist to enforce.

Contract Drugs List (CDL)

Medi-Cal's formulary. Removal from it — as happened to Wegovy, Zepbound, and Saxenda for weight indications on January 1, 2026 — is how a California coverage cut is mechanically executed.

Contraindication

A condition making a drug inappropriate to use. For the GLP-1 class: personal or family history of medullary thyroid carcinoma, MEN 2, and prior serious hypersensitivity to the agent lead the list.

Dose-flat pricing

A program price that does not change as the dose titrates upward. The structure that protects a budget through escalation — its opposite, tiered pricing, can turn a cheap start into an expensive maintenance.

Dual agonist

A drug activating two receptor pathways. Tirzepatide is the class example: a GIP and GLP-1 receptor agonist, which is the mechanistic reason its trial weight-loss numbers run ahead of semaglutide's.

EPSDT

Early and Periodic Screening, Diagnostic and Treatment — the federal Medicaid benefit requiring individualized medical-necessity coverage for enrollees under twenty-one, even where a state excludes a drug class for adults. The under-21 door that survives every 2026 state cut.

Essentially a copy

The regulatory concept barring compounders from producing what amounts to a duplicate of a commercially available drug. Restated by the FDA in spring 2026 as the approved oral products arrived — the legal squeeze on routine compounded versions.

Fee-for-service (FFS)

Medicaid's direct-payment arrangement, where the state's own preferred drug list governs. The baseline the fifty-state trackers report — your managed-care plan's formulary can differ in either direction.

Form 483

The FDA inspector's written list of observed deficiencies after an inspection. Not a verdict — the questions are what was observed and how the firm responded — but a sterility-touching 483 at a compounder is worth reading before you buy.

Formulary

The list of drugs a plan covers, usually in preference tiers. The first thing to check and the thing that changes quarterly — a six-month-old 'no' may be stale.

GIP

Glucose-dependent insulinotropic polypeptide, the second incretin hormone. Tirzepatide's additional target; semaglutide does not touch it.

GLP-1

Glucagon-like peptide-1, a gut incretin hormone that slows gastric emptying, moderates appetite signaling, and supports insulin response. The class name for the drugs that mimic it.

Grandfathering

Policy language letting existing patients continue under old rules after a change. 2026's state Medicaid cuts mostly offered the weaker cousin — existing authorizations honored only until renewal — which is why renewal dates, not announcement dates, are the ones that matter.

Incretin

The gut-hormone family (GLP-1, GIP) released after eating that amplifies insulin secretion and signals satiety. The physiological system this entire drug class borrows.

Indication

The specific use a regulator has approved a drug for. The load-bearing word in coverage law: the same molecule can be state-optional for weight loss and federally mandatory for cardiovascular risk reduction, sleep apnea, kidney disease, or MASH.

Lock-in rate

A promotional structure where the enrolled price is contractually held for as long as the plan stays active — NexLife's 'Flat Forever' term is the dataset's current example. Operator-stated terms; screenshot them at checkout.

MACE

Major adverse cardiovascular events — heart attack, stroke, cardiovascular death — the composite endpoint cardiovascular outcome trials measure. The SELECT trial's twenty-percent MACE reduction is what created Wegovy's cardiovascular indication.

Maintenance dose

The ongoing dose after titration — 2.4 mg weekly for semaglutide in weight management; commonly 10 to 15 mg for tirzepatide. The only honest basis for price comparison, because it's the price you pay for the rest of the year.

MASH

Metabolic dysfunction-associated steatohepatitis, the liver disease formerly called NASH. Wegovy's 2025 accelerated-approval indication for the noncirrhotic form with fibrosis — a non-weight door that works in every state.

MedWatch

The FDA's adverse-event reporting portal. Where a patient or clinician reports a suspected product problem — the mechanism behind every adverse-event tally cited on this site.

MEN 2

Multiple endocrine neoplasia syndrome type 2, a hereditary condition predisposing to medullary thyroid carcinoma. With personal or family MTC history, the class contraindication on every label.

Managed care organization (MCO)

A private plan administering Medicaid benefits under state contract — how most enrollees actually receive drug coverage. Its formulary can differ from the state FFS baseline, which is why the second phone call matters.

Medically accepted indication

The Medicaid Drug Rebate Program's coverage trigger: FDA-approved uses (plus certain compendia-supported ones) that participating states must generally cover. The legal machinery behind the indication doors.

Multidose vial

A vial containing several doses the patient draws with a syringe — the standard compounded-GLP-1 format, and the format behind most reported dosing errors. Units-to-milligrams arithmetic is the safety skill the format demands.

NAION

Non-arteritic anterior ischemic optic neuropathy, a rare optic-nerve event examined in 2024–2025 semaglutide safety reviews; European regulators concluded it a very rare potential side effect. Sudden vision change on any GLP-1 is a same-day call.

Nonresident pharmacy license

The license a pharmacy needs from your state's board to ship into your state, on top of its home-state license. The second of the two license checks — and the one telehealth buyers most often skip.

Off-label

Prescribing an approved drug for an unapproved use — legal for clinicians, rarely covered by payers. Ozempic for weight loss is the class's canonical example.

Orforglipron

The first small-molecule oral GLP-1 receptor agonist, FDA-approved April 1, 2026 for chronic weight management. A pill without peptide handling requirements — and a named drug on the BALANCE negotiated list.

Outsourcing facility

See 503B — the formal statutory name for the category.

PCAB accreditation

Pharmacy Compounding Accreditation Board certification (administered with ACHC): third-party verification of a compounding pharmacy's quality practices. Ask for the certificate number, verify it with the accreditor, and treat a logo without a number as decoration.

Peer-to-peer review

A phone review between your prescriber and the plan's medical director after a PA denial. The appeal step that most often reverses a documentation-shaped 'no.'

Preferred drug list (PDL)

A state Medicaid formulary's preference tiering. Preferred agents move with less friction; non-preferred ones need prior authorization — Wisconsin's GLP-1 class is the working example on this site.

Prior authorization (PA)

A payer's pre-approval requirement: the prescriber submits documentation proving criteria are met before the pharmacy can fill. A requirement, not a denial — and the paperwork battlefield where most coverage outcomes are actually decided.

Rankable

This site's methodology term: a program with a published maintenance-dose price that can therefore be compared honestly. Start-only and funnel-gated prices are recorded but never ranked, because a number you can't hold a program to is not a price.

Rate card

A program's published price schedule across plan terms. This site stores standard and promotional cards side by side — the promotional figure is never silently substituted.

Rebate (Medicaid Drug Rebate Program)

The statutory manufacturer discounts (roughly forty percent in aggregate for this class) that participating states receive — and the program whose coverage rules create the medically-accepted-indication obligations behind the doors.

Salt form

A chemically modified version of a drug molecule (semaglutide sodium, semaglutide acetate) that is not the approved base compound. A red flag in compounded products: the approved trials used the base molecule, and 'research-grade salt' is a phrase to walk away from.

SELECT trial

The cardiovascular-outcomes trial of semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease, without diabetes — about a twenty-percent MACE reduction, published 2023, indication granted March 2024. The study that built the cardiovascular door.

Semaglutide

The GLP-1 receptor agonist in Ozempic (T2D), Wegovy (weight management, CV risk, MASH), and Rybelsus (oral, T2D). The most-prescribed molecule in the class and forty percent of this site's coverage by design.

Service authorization (SA)

Some states' term (Virginia's, for example) for prior authorization on the Medicaid side. Same machinery, different letterhead.

Step therapy

A payer requirement to try cheaper agents first — phentermine, orlistat, and kin before a GLP-1 in several state criteria. Document the trial and the failure; undocumented steps don't count.

SURMOUNT / SURPASS

The tirzepatide trial programs: SURPASS in type 2 diabetes, SURMOUNT in weight management — SURMOUNT-1's roughly twenty-percent average body-weight reduction at the top dose is the number that made the molecule famous.

STEP program

The semaglutide 2.4 mg weight-management trials (STEP 1's roughly fifteen-percent average reduction leading). The evidentiary base under Wegovy's original indication.

Telehealth

Remote clinical care — the intake-and-prescribing layer of every program in this database. The clinician still needs a license in your state; distance changes the room, not the rules.

Tirzepatide

The dual GIP/GLP-1 receptor agonist in Mounjaro (T2D) and Zepbound (weight management, OSA). The strongest weight-loss trial numbers in the class and sixty percent of this site's coverage by design.

Titration

The scheduled stepwise dose escalation every GLP-1 label requires — month by month from the starter dose toward maintenance — to manage GI tolerability. The schedule your program should hand you in writing.

Units (insulin syringe)

The graduations on standard syringes (100 units = 1 mL) used to draw from multidose vials. The units-to-milligrams conversion depends on the vial's concentration — the arithmetic behind most at-home dosing errors and the reason our converter page exists.

Utilization management

The payer toolkit — PA, step therapy, quantity limits, refill windows — that governs access after 'covered' is technically true. Coverage is a door; utilization management is the hallway.

Warning letter

The FDA's formal notice of significant violations, published in a searchable public database. The 2025–2026 GLP-1 waves cited marketing equivalence claims and undisclosed pharmacies far more often than compounding itself — read what the letter actually says.

Wind-down period

The transition time a final rule typically allows between publication and full effect. The reason a finalized 503B exclusion would reshape the market on a schedule, not overnight — and the reason panic-switching ahead of any rule is paying a premium for a date nobody has.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.